Transcatheter Aortic Valve Replacement in patients with low ejection fraction: comparable outcomes with good ejection fraction patients.

Original title: Relation of Pre-procedural Assessment of Myocardial Contractility Reserve on Outcomes of Aortic Stenosis Patients with Impaired Left Ventricular Function Undergoing Transcatheter Aortic Valve Implantation Reference: Israel M. Barbash et al. Am J Cardiol. 2014, Epub ahead of print.

 

Transcatheter aortic valve replacement (TAVI) is associated with a better left ventricular function (LV) in patients with aortic stenosis (AS) and LV dysfunction; however, post-TAVI clinical outcomes in patients with low ejection fraction (LVEF) are still under discussion.

This study evaluated the baseline procedural and long term outcomes of patients with low LVEF undergoing TAVI and the prognostic use of pre TAVI balloon aortic valvuloplasty (BAV) and dobutamine stress echocardiography (DSE) to predict TAVI benefit.

All severe symptomatic AS patients undergoing TAVI between 2007 and 2013 were analyzed. Two groups were compared: the normal group, with normal LV function (LVEF > 45 %) and abnormal (LVEF ≤ 45 %) at baseline. 371 patients were included, 272 (73 %) had preserved LVEF and 99 (27%) low had LVEF. Patients with low LVEF had higher Society of Thoracic Surgeons Score and EuroSCORE.

Short and long term mortality was similar in both groups (one year mortality: 22,2 % normal LVEF vs. 22,4 % abnormal LVEF, p = 0,79). In the low LVEF group, 24% of patients showed improvement at 30 days (≥ 10 %). This group had a lower rate of one year mortality compared to those that did not show LVEF improvement (8 % vs 27 %, p = 0,06).

On the other hand, contractile reserve in dobutamine stress echocardiography did not predict LVEF recovery in patients with low LVEF, but did predict lower mortality. LVEF recovery after TAVI was able to predict greater improvement of post TAVI LVEF.

Conclusion

Patients with severe AS and impaired LV function will benefit from TAVI and their post TAVI outcomes are comparable to those of patients with preserved LVEF. Both DES and TAVI provide complementary data with regard to LVEF recovery and peri procedural mortality.

Editorial Comment

We often wonder what the outcome our low LVEF patients will be after TAVI and in this study we can see that, globally, mortality rate is similar to that of preserved LVEF patients, which is not the case of surgical aortic valve replacement, since LVEF predicts worse outcomes and higher mortality both in STS and EuroScore.

Although only 25% of patients recovered more than 10 % of LVEF at 30 days, the global benefit could be seen in the whole group, and patients that improved LVEF had lower mortality. Pre TAVI aortic valvuloplasty seems to be a good tool to tell patients that will improve LVEF after TAVI from those who will not. The rise of contractility with dobutamine (contractility reserve) seems a good tool to predict lower mortality, though it will not assure LVEF recovery.

Courtesy of Dr. Matías Sztejfman.
Interventional Cardiologist.
Sanatorio Güemes. Buenos Aires, Argentina.

Dr. Matías Sztejfman

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...